Xenetic

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology designed to target patient-specific tumor neoantigens. The company is developing cell-based therapies targeting unique B-cell receptors on the surface of malignant cells in individual patients for the treatment of B-cell lymphoma. XCART™ has the potential to drive a robust pipeline of therapeutic assets for high-value oncology indications. Xenetic is leveraging its proprietary drug delivery platform, PolyXen®, in collaborations with biotechnology and pharmaceutical companies. PolyXen® has demonstrated its ability to enhance the half-life and other pharmacological properties of next-generation biologics.